Skip to main content
ROIV
NASDAQ Life Sciences

Mosliciguat Hits Phase 2 Primary Endpoint in PH-ILD; Phase 3 Underway for Roivant

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$41.29
Mkt Cap
$25.231B
52W Low
$12.54
52W High
$37.97
52W Position info
229% above low
Off High info
at 52W high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

ROIV has more than doubled off its 52-week low of $12.54.

Summary

Positive Phase 2 PHocus results for mosliciguat in PH-ILD were announced, showing a -56.3% placebo-adjusted PVR reduction and initiating the Phase 3 PHrontier study.

Updates

  1. · Wiseek News — TD Cowen raised its target to $55 from $50 and HC Wainwright to $47 from $41, both maintaining Buy ratings.


Key Events · Product Development and Regulatory · ROIV

  • Phase 2 PHocus Primary Endpoint Met

    At Week 16, mosliciguat achieved a -56.3% placebo-adjusted reduction in pulmonary vascular resistance (p<0.0001) — the highest ever reported in a randomized controlled PH trial.

  • Secondary Endpoints Also Positive

    Six-minute walk distance improved by +35.2 meters (p=0.0027) and NT-proBNP fell -53.2% (p=0.0002) versus placebo, with effects strengthening to +52.7m and -75.9% at Week 24.

  • Phase 3 PHrontier Study Initiated

    The registrational Phase 3 trial is enrolling approximately 375 patients worldwide, with the goal of rapidly advancing mosliciguat toward approval.

  • Favorable Safety Profile

    Mosliciguat was well tolerated, with lower cough incidence than placebo (12.1% vs 18.2%) — a key differentiator versus inhaled prostacyclins.


Analysis · ROIV · Life Sciences

The Phase 2 PHocus results for mosliciguat delivered the highest pulmonary vascular resistance reduction ever reported in a randomized controlled PH trial (-56.3% placebo-adjusted, p<0.0001), alongside clinically meaningful improvements in six-minute walk distance and NT-proBNP. With the Phase 3 PHrontier study already enrolling, mosliciguat is positioned as a potential first-in-class therapy for a disease with median survival of just 1.5-2 years. This represents a major pipeline de-risking event for a company whose valuation has been driven by LISRAYA's recent FDA approval.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ROIV was trading at $41.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $25.2B. The 52-week trading range was $12.54 to $37.97. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ROIV - Latest Insights

ROIV
Nov 09, 2026, 7:36 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $41.37
Real-time Price: $38.68 info
Change: -$2.69 (-7%) info
Market Cap: $28.008B info
ROIV
Nov 09, 2026, 7:17 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $41.00
Real-time Price: $38.68 info
Change: -$2.32 (-6%) info
Market Cap: $28.008B info
ROIV
Nov 09, 2026, 7:01 AM EST
Source: Reuters
Importance Score:
7
Price at Filing: $40.39
Real-time Price: $38.68 info
Change: -$1.71 (-4%) info
Market Cap: $28.008B info
ROIV
Oct 21, 2026, 7:05 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $36.20
Real-time Price: $38.68 info
Change: +$2.48 (+7%) info
Market Cap: $28.008B info
ROIV
Oct 21, 2026, 7:00 AM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $36.60
Real-time Price: $38.68 info
Change: +$2.08 (+6%) info
Market Cap: $28.008B info